Sharda Cropchem Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 15 Jul 2026 | Fertilizers & Agrochemicals | Market Cap: ₹7.1K Cr
Revenue growth guidance for FY27 is expected to be 10% to 15%, with potential to go higher or lower based on various factors (Page 12, 13). Revenue growth guidance for FY27 is expected between 10% to 15%, with potential to go higher or lower based on external factors.
From Sharda Cropchem Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹761
Market Cap
₹7.1K Cr
P/E Ratio
11.3
How does Sharda Cropchem Ltd rank in Fertilizers & Agrochemicals?
Compare Sharda Cropchem Ltd against every Fertilizers & Agrochemicals company this quarter on revenue, margins and earnings-call signals.
Sharda Cropchem Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹2.1K Cr, net profit ₹319 Cr.
Full financials →📊 Revenue & Sales Performance
- →Revenue growth guidance for FY27 is expected to be 10% to 15%, with potential to go higher or lower based on various factors (Page 12, 13).
- →Volume growth projection for FY27 is around 15% (Page 13).
- →Growth is driven by both existing product portfolio and new registrations, though registration timelines are uncertain and approvals have slowed down (Page 11, 17-18).
- →Limited competition due to extended registration approval timelines may help in maintaining/improving realizations (Page 18).
- →Company has a global market share of about 5%, implying significant scope for market share expansion which can lead to business growth (Page 18).
- →Non-agro segment expected to grow 5%-10% with improving margins (Page 14).
- →New products launched in last 3-4 years contribute about 30% to revenue (Page 13).
- →Overall growth is supported by increasing global population and agricultural demand (Page 16).
📈 Profitability & Margins
- →Revenue growth guidance for FY27 is expected between 10% to 15%, with potential to go higher or lower based on external factors.
- →Volume growth for FY27 is anticipated around 15%.
- →Gross margins are expected to remain stable around 35%, with some fluctuations possible.
- →EBITDA margin guidance for FY27 is maintained in the range of 18% to 20%.
- →EPS and PAT growth are likely to follow the revenue and margin trends, supported by strong operating performance.
- →The company is optimistic about continued product registrations impacting future growth but registration timing is uncertain.
- →Forex impacts are unpredictable and not factored into earnings guidance.
- →Overall, management is confident of sustaining healthy profitability through disciplined execution and market positioning.
🏗️ Capital Expenditure Plans
- →For FY26, Sharda Cropchem's capital expenditure (CAPEX) stood at INR 505 crores.
- →No specific details on future or ongoing CAPEX/capital investments were explicitly mentioned in the transcript.
- →The company focuses on product registrations and expanding its market share globally, which may imply investment in registrations and marketing.
- →The business model emphasizes marketing and registrations rather than trading or manufacturing expansions.
- →Growth is expected from increasing registrations, market share, and leveraging an IP-led model, rather than large-scale CAPEX.
- →Any potential future strategic investments would relate to enhancing registrations and product pipelines, but no direct mention of new or planned capital investments was made.
💰 Fundraising & Capital Structure
📋 Order Book & Pipeline
- →The transcript does not explicitly mention the current or expected order book or pending orders in quantitative terms.
- →However, the management indicates optimism regarding registrations and business growth despite uncertainties in registrations and approvals.
- →They mention having about 1,000 molecules currently under application for registration, expecting many registrations to come through in the financial year, though timing is uncertain due to bureaucratic processes.
- →The company emphasizes that growth is not solely dependent on new registrations but also on expanding market share from the current global share of about 5%.
- →They highlight strong customer confidence in their ability to supply promised products on time and at promised value, which supports business continuity.
- →Overall, while no specific order book figures are disclosed, the pipeline of registrations and customer trust underpin expected business growth.
Key Metrics
Frequently Asked Questions
What were Sharda Cropchem Ltd Q4 FY26 results?
Revenue growth guidance for FY27 is expected to be 10% to 15%, with potential to go higher or lower based on various factors (Page 12, 13). Revenue growth guidance for FY27 is expected between 10% to 15%, with potential to go higher or lower based on external factors.
What is Sharda Cropchem Ltd share price analysis?
Sharda Cropchem Ltd currently shows a neutral. The stock trades at a P/E of 11.3 with a market cap of ₹7,095 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sharda Cropchem Ltd planning capital expenditure?
For FY26, Sharda Cropchem's capital expenditure (CAPEX) stood at INR 505 crores.
Keep Sharda Cropchem Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.